ARA-290 (14mg)

What is ARA-290?

ARA-290 is a synthetic peptide derived from the helical domain of erythropoietin (EPO), engineered to selectively activate the innate repair receptor (IRR). ARA-290 has been studied for its potential to modulate cellular stress responses and support tissue protection in preclinical models. Its receptor-binding profile is functionally distinct from that of full-length EPO, and its non-glycosylated structure simplifies synthesis while facilitating standardized use across research workflows.

What Are the Key Features of ARA-290?

This 14 mg vial is designed for in vitro and in vivo protocols requiring larger working quantities. A lower-dose variant, ARA-290 (10mg), is also available for dose-ranging or smaller-scale experiments. Both formats are presented as lyophilized powder to support stability during shipping and storage. Key specifications include:

• Molecular Formula: C₅₁H₈₄N₁₆O₂₁
• Molecular Weight: 1257.3 g/mol
• CAS Number: 1208243-50-8
• Purity: ≥98% by HPLC and MS
• Synonyms: Cibinetide, PHBSP
• For laboratory research use only.

How is ARA-290 Synthesized?

ARA-290 is produced using solid-phase peptide synthesis (SPPS), which enables controlled, sequence-specific assembly of its amino acid chain without reliance on biological expression systems. This method ensures consistency across batches and minimizes the risk of contamination. Post-synthesis purification is followed by analytical verification via HPLC and MS to confirm identity and structural integrity. Other short-chain research peptides, such as Cartalax, undergo the same SPPS-based workflow and share equivalent analytical verification standards across the field.

What is ARA-290 Being Studied For? What Are Its Possible Benefits?

ARA-290 has been studied across several research contexts where healing & regenerative processes are under active investigation, with particular focus on models involving peripheral nerve damage, metabolic disruption, and inflammatory tissue injury. The following areas represent the primary preclinical research directions documented in the literature:

• Peripheral neuropathy: studied for potential nerve fiber repair and neuropathic pain reduction in diabetic animal models
• Inflammation: under investigation for effects on cytokine activity and macrophage polarization
• Metabolic function: being researched in models assessing insulin sensitivity and pancreatic beta-cell viability
• Tissue repair: studied in wound-healing and soft tissue injury settings

All findings referenced above are preclinical and do not constitute established clinical evidence.

How Does ARA-290 Work in Research Studies?

In laboratory models, ARA-290 is believed to bind selectively to the IRR, a heteroreceptor complex upregulated under cellular stress. It initiates cytoprotective signaling cascades without engaging the classical EPO receptor or triggering erythropoiesis. This selectivity allows researchers to study tissue-level effects independently of hematopoietic outcomes. The peptide B7-33 operates on a similar principle of selective receptor targeting, and both compounds are referenced in the literature exploring how short-chain peptides can elicit site-specific biological responses in injury and inflammation models.

What Dosing Information Exists for ARA-290?

Published preclinical studies report subcutaneous or intraperitoneal dosing of ARA-290 at 30–60 nmol/kg in murine models, with in vitro concentrations typically ranging from 0.1 nM to 100 nM depending on cell type and endpoint. Stock solutions are commonly prepared at 1 mg/mL in sterile aqueous buffer, with working dilutions prepared as needed per the experimental design. The 14 mg vial format accommodates multi-group or longitudinal study designs without requiring separate procurement at each time point. No human dosing guidelines exist; all concentrations cited apply exclusively to preclinical and in vitro laboratory contexts.

How Should ARA-290 Be Stored and Handled?

• Lyophilized ARA-290 should be stored at −20°C in a dry environment, shielded from light and moisture.
• Under these conditions, stability is expected for up to 24 months from manufacture (refer to the certificate of analysis (CoA) for lot-specific shelf-life data).
• Reconstituted solutions should be held at 2–8°C and consumed within 48–72 hours.
• Repeated freeze-thaw cycles should be avoided; preparation of single-use aliquots is recommended to maintain compound integrity over time.

Where Can I Read More Research About ARA-290?

1. Brines M, Dunne AN, van Velzen M, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015;20(1):658-666. Published 2015 Mar 13. doi:10.2119/molmed.2014.00215
2. Dahan A, Brines M, Niesters M, Cerami A, van Velzen M. Targeting the innate repair receptor to treat neuropathy. Pain Rep. 2016;1(1):e566. Published 2016 Aug 9. doi:10.1097/PR9.0000000000000566
3. Heij L, Niesters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med. 2012;18(1):1430-1436. Published 2012 Nov 15. doi:10.2119/molmed.2012.00332
4. van Velzen M, Heij L, Niesters M, et al. ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs. 2014;23(4):541-550. doi:10.1517/13543784.2014.892072
5. Swartjes M, van Velzen M, Niesters M, et al. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain. 2014;10:13. Published 2014 Feb 16. doi:10.1186/1744-8069-10-13

  This product is intended for laboratory research use only and is not approved for human or veterinary use.